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1. Introduction 
The development of the radio-immunoassay, 
initiated by Berson et al. [ 1 ] , has permitted estimation 
of antibodies and antigens to a high degree of sensitivity. 
This is particularly true in endocrinology, where bio- 
assays are often difficult, time consuming and expen- 
sive. 
In this type of immunoassay, the antigen occupies 
a central position [2] but its label, need not be a 
radionuclide. Haimovich et al. used protein-bacterio- 
phage conjugates for the assay of antibodies and 
antigens [3,4] and the preparation of enzyme-anti- 
body and enzyme-antigen conjugates, mainly for 
histological purposes has been described [ 5,6] . 
We have conjugated the antigen human chorionic 
gonadotrophin (HCG) to the enzyme horse radish 
peroxidase (HRP) and used purified conjugates for 
‘enzyme-immunoassay’ of antibody and antigen**. 
2. Materials and methods 
2.1. Reagents 
HCG was prepared by van Hell et al., according to 
procedures previously described [7, 81 . Antisera were 
raised in rabbits against highly purified HCG as described 
earlier [9] . Antiserum against rabbit y-globin was pre- 
pared by immunization of a sheep with a y-globulin 
preparation obtained by DEAE-cellulose chromatography 
* Requests for reprints: Organon Library, Oss, The Netherlands. 
** USA patent application 762120, filed 24th September 1968; 
Dutch patent application 7018838, filed 28th December 
1970. 
[lo] The sheep received 0.5, 1 and 2 mg intramuscularly 
in complete Freund’s adjuvant at two-week intervals, 
followed by a booster injection of 1 mg 2 weeks later. 
HRP, grade IV, RZ = 0.6, was obtained from Miles- 
Seravac, Maidenhead, Berks.. England: glutaraldehyde 
as a 25% aqueous solution from Schuchardt, 8000 
Miinchen, W. Germany; lactalbumin from DMV De 
Meijerij, Veghel, the Netherlands; 5-aminosalicyclic 
acid from Ega-Chemie, 7924 Steinheim/Albuch, Ger- 
many; hydrogen peroxide 30% and microcrystalline 
cellulose from Merck; Lyphogel (a product of Gelman 
Instrument Company) from Hawsley and Sons, 
Lancing, Sussex, England; CNBr from Fluka A.G., 
Buchs, Switzerland. 
2.2. Equipment 
Ultracentrifuge runs were performed in an Inter- 
national Equipment Company B-60 preparative ultra- 
centrifuge. Absorbance measurements were made 
with a Gilford 300-N micro-sample spectrophotometer, 
and with an LKB Uvicord. 
2.3. Preparation of immune adsorbents 
Antibodies against HCG and against rabbit y-globulin 
(RGG) were coupled to cellulose. y-Globulin fractions 
of antisera were prepared by precipitation with solid 
Na2S04 (160 mg/ml for sheep sera, 180 mg/ml for 
rabbit sera) at room temperature. These y-globulin 
fractions were coupled to either m-aminobenzyl- 
oxymethyl cellulose which had been reprecipitated 
from a cuprammonium solution and diazotized by 
Gurvich’s method, as described by Campbell and 
Weliky [ 1 l] , or to microcrystalline cellulose activated 
with CNBr [ 12,131. The immune adsorbents are 
designated as follows 
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Diazotation (a-I-ICC)-1 (a-RGG)-I 
CNBr (a-HCG)-II (a-RGG)-II 
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2.4. Preparation of HCG-HRP conjugates 
5 mg HCG (5000 IU/mg) and 20 mg HRP were 
dissolved in 2 ml 0.05 M phosphate-citrate buffer pH 
7, containing 1% glutaraldehyde and shaken for 2-3 
hr at room temperature. Insolubilized protein was 
removed by centrifugation at 1000 g for 10 min. 
Excess glutaraldehyde was removed by gel filtration 
with Sephadex G-SO. The enzymecontaining fractions 
were pooled, concentrated by addition of an appropriate 
amount of lyphogel, layered over a sucrose density 
gradient (20-60%), and centrifuged at 5” for 16 hr 
at 283,000 g. Fractions were collected after perfora- 
tion of the bottom of the tube. 
another 30 min. (a-RGG)-I or -11 suspended in 0.3 ml 
was added, and the reaction mixture was shaken for 2 
hours. Centrifugation and enzyme-assay were performed 
as described above. 
All solutions were made in 0.02 M phosphate buf- 
fer pH 6.0, containing 0.1% lactalbumin. 1 g lactal- 
bumin was stirred with 100 ml phosphate buffer for 
15 min, filtered over Hyflo filter aid and diluted to 
0.1% on the basis of the measurement of Azso using a 
standard curve. All procedures took place at room 
temperature. 
No HCG was added and the first incubation was 
omitted for the determination of the percentage 
enzymatically active conjugate which could be bound 
to excess a-HCG. This property will be indicated as 
‘immune reactivity’ of the conjugate. The first incuba- 
tion was also omitted when antiserum dilution curves 
were determined. 
2.5. Haemagglutination inhibition test for HCG 3. Results 
The procedure described by Wide [ 141 was used, 
with some modifications [9]. 
2.6. Peroxidase assay 
Density gradient centrifugation was used to 
separate HCG-bound HRP from the unreacted material. 
A typical case is shown in fig. 1. A reasonably sharp 
A substrate solution was prepared by dissolving 80 
mg 5-aminosalicyclic acid in 100 ml 0.02 M phosphate 
buffer pH 6.0, to which 10 ~130% Hz02 was added. A 
1 ml enzyme sample containing I-20 mIU was added 
to 1 ml of the freshly prepared substrate solution. The 
absorbance at 450 run was read after incubation for 1 
hr at room temperature. 
2.7. Enzyme-immunoassay procedures 
(A) Solid phase (SP) method: A 0.5 ml sample 
containing HCG and 0.4 ml (a-HCG)-I or -II suspension 
were incubated during rotation for 2 hr. 0.1 ml con- 
jugate solution containing about 10 mIU HRP activity 
was added, and incubation was continued for 2 hr. 
After centrifugation for 5 min at 2000 rpm, 0.5 ml was 
taken from the supernatant, diluted 1: 1 with 0.02 M 
phosphate buffer, and assayed for HRP-activity as 
described under 2.6. 
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(B) Double antibody solid phase (DASP) method 
(151: A 0.5 ml sample containing HCG and 0.1 ml 
diluted a-HCG serum were incubated for 30 min. Then 
0.1 ml conjugate solution containing about 10 mIU 
HRP activity was added and incubation continued for 
Fig. 1. Fractionation of an HCG-HRP conjugate by density 
gradient centrifugation (section 2.4). Fractions were collected 
from the bottom of the tube and pooled as indicated by bats. 
- absorbance at 280 nm 
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Fig. 2. Antiserum dilution curves of a high- and low- HCG/ 
HRP-ratio conjugate (CD and CI respectively). 100% enzyme 
activity equals an A:sy of about 0.400 in the enzyme-assay. 
separation between conjugated and unconjugated HRP 
is obtained, as can be seen from the decrease in the 
immune reactivity (cf. section 2.7) around fraction 30. 
Fractions 5-27, showing more than 80% immune reac- 
tivity, were chosen for use in our assays. They contained 
3, . 
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Fig. 3. Standard curves for HCG assay using a low (CI) and a 
high (CID HCG/HRP ratio conjugate. The antiserum dilutions 
for the various curves were: CIa: l/5000; CIb: l/10000; CII: 
l/1250. 100% enzyme activity equals an A:g of about 0.400 
in the enzyme-assay. 
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Fig. 4. Comparison of solid phase and double antibody solid 
phase systems in enzyme-immunoassay, using conjugate GIL 
100% enzyme activity equals an Aig of about 0.400 in the 
enzyme-assay. 
Curve 1: (a-RGG)-II, Antiserum dilution 
Curve 2: (a-RGG)-I, 1 l/2000 
Curve 3: (a-HCG)-II, 1.2 mg/tube 
Curve 4: (a-HCG)-I, 0.1 mg/tube 
Details are described in section 2. 
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HAEMAGGLUTINATION INHIBITIDN ASSAY W/ML 
Fig. 5. Correlation between HCG-content of 15 pregnancy 
urines as measured by haemagglutination i hibition assay and 
by enzyme-immunoassay. 
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some 5% of the total enzyme activity. The faster 
sedimenting conjugates in fractions 5-14 showed a 
lower HCG/HRP ratio than the conjugates in fractions 
15-27. Therefore, they were combined into two 
pools, CI and CII respectively. 
determine which conjugate is to be used in a given test 
system. 
As shown in fig. 2, CII requires 2-3 times more 
a-HCG than CI to attain the same percentage binding 
of its enzyme activity. Standard curves obtained with 
these pools showed a corresponding difference in 
sensitivity, CI giving the most sensitive assay (fig. 3). 
As in the radio-immunoassay, the sensitivity can be 
raised by using a higher antiserum dilution. The results 
shown in figs. 2 and 3 were obtained with the DASP 
method (section 2.7B), using (a-RGG)-I (section 2.3). 
Separation between antibody-bound and free 
conjugate is as important in enzyme-immunoassay as 
it is in radio-immunoassay. We used the SP and the 
DASP method [ 151. The latter was found to be superior 
for two reasons: 
A comparison of the SP and DASP methods is 
shown in fig. 4. Little difference in sensitivity was 
found between the DASP-systems employing (a-RGG)-I 
and -11. However, both SP systems were markedly less 
sensitive, (a-HCG)-I giving the least sensitive system. 
The applicability of the test system was illustrated by 
the determination of.HCG in urines from 15 pregnant 
and 15 non-pregnant women, both by DASP enzyme- 
immunoassay - adjusted to a sensitivity level of 0.4 
III/ml - and by a haemagglutination inhibition assay 
with a sensitivity of 1 III/ml. The correlation between 
these test methods is shown in fig. 5. The HCG con- 
centrations in all non-pregnancy urines were below the 
detection of either test. 
(a) Higher sensitivity. This might be explained by 
the assumption that some of the antibodies on 
the (a-HCG)-immune adsorbents are accessible 
for HCG, but not for the high-molecular-weight 
conjugates, while others are accessible for all 
reaction partners. Excess of (a-HCG)-cellulose 
impairs the sensitivity of the test system while 
excess of (a-RGG)-cellulose does not. 
(b) Better duplicate determinations, possibly because 
an (a-HCG) solution can be added more accurate- 
ly than an (a-HCG)-cellulose suspension. The 
amount of (a-RGG)-cellulose in DASP systems is 
not critical, since it has to be used in excess. 
The sensitivity of the enzyme-immunoassays i with- 
in the range of haemagglutination inhibition or comple- 
ment fixation assays, when using SP systems. DASP 
systems were 1 O-20 times more sensitive, but did not 
reach the high sensitivity of radio-immunoassay. The 
enzyme-immunoassay could be performed on urine 
samples and this may be important for clinical applica- 
tions. 
4. Discussion Acknowledgement 
Density gradient centrifugation could be used for 
obtaining conjugates with an ‘immune reactivity’ (cf. 
section 2.7) of 80% or more. Since the immune 
reactivity of the unpurified conjugate is about 5%, a 
purification of at least 16-fold was achieved. The low 
figure for the unpurified conjugate may reflect the 
limited reactivity of HRP [ 161. 
Our thanks are due to Miss.M. Langeveld, Miss G.T. 
Snoek and Mr. H.H.Th. Raymakers for their skilled 
technical assistance. 
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